Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens

Diğer sürümleri göster (1)

Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian adenoviruses do not suffer from the same drawbacks. We have con...

Detaylı Bibliyografya
Asıl Yazarlar:	Antrobus, R, Coughlan, L, Berthoud, T, Dicks, MD, Hill, A, Lambe, T, Gilbert, S
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Nature Publishing Group 2014

Benzer Materyaller

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
Yazar:: Antrobus, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Yazar:: Folegatti, P, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Yazar:: Pedro M. Folegatti, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Yazar:: Zhang, C, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Yazar:: Cheng Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
Yazar:: Adam Berg, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
Yazar:: Dicks, M, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Yazar:: Charlotte Davis, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
Yazar:: Ashley C. Beavis, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
Yazar:: O'Hara, G, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Yazar:: Hermosilla, E, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Yazar:: Eduardo Hermosilla, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
Yazar:: Sharpe, HR, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
Yazar:: Jinnam Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
Yazar:: Tanie Natung, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Yazar:: Hannah R. Sharpe, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
Yazar:: Anupa Mary Job, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Yazar:: Ogbe, A, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
Yazar:: Moreira Folegatti, P
Baskı/Yayın Bilgisi: (2021)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
Yazar:: Bas de Laat, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
Yazar:: Rujittika Mungmunpuntipantip, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Yazar:: Ane Ogbe, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Yazar:: Alharbi, N, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Yazar:: Stedman, A, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
Yazar:: Simone Barocci, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
Yazar:: Alharbi, N, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Simian adenoviruses as vaccine vectors
Yazar:: Morris, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Simian adenoviruses as vaccine vectors
Yazar:: Morris, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
Yazar:: Giorgio Berlot, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
Yazar:: Lea Krutzke, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
Yazar:: Tamara Garibashvili, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Yazar:: Jennifer Serwanga, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
Yazar:: Ewer, K, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Marchevsky, NG, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
Yazar:: Edmund G.-T. Wee, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys
Yazar:: Neeltje van Doremalen, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Natalie Gabrielle Marchevsky, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Yazar:: Tao Ni, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
Yazar:: Manabendra Basu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
Yazar:: Gerardo Casucci, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)